Accelerators
Memorial Sloan Kettering Therapeutics Accelerator (2025-current)
Frezent is a part of MSK Therapeutics Accelerator program cohort 2025. The program focuses on establishing close collaborations leveraging MSK’s expertise to de-risk critical points in therapeutics development.
Frezent has gained streamlined access to MSK facilities and infrastructure, as well as the opportunity to collaborate with its leading clinical and scientific experts to build a strong clinical strategy. Through the accelerator program, Frezent also receives support from MSK’s marketing team and IND writing and advising group.
The program will help Frezent connecting with clinical experts to develop clinical trial protocols for MSK’s specialized care setting and leverage the institution’s infrastructure for robust correlative studies.
SOSV IndieBio NY (2023-2024)
Frezent is an alumnus of the IndieBio cohort 7 (Fall 2023 program), a prestigious and highly selective accelerator program designed to support early-stage biotech startups with essential resources and mentorship.
Frezent received valuable entrepreneurship education and gained access to a robust network of industry experts, including leaders in biotech innovation, regulatory strategy, intellectual property, and venture funding, over the course of the program.
Since completing the program, Frezent has continued to receive the mentorship and strategic support from IndieBio to refine its business strategy and accelerate project advancement.